Mitochondrial DNA (mtDNA) mutations have been described in almost all types of cancer. However, their exact role and timing of occurrence during tumor development and progression are still a matter of debate. A Vogelstein-like model of progression is well established for endometrial carcinoma (EC), however, mtDNA has been scarcely investigated in these tumors despite the fact that mitochondrial biogenesis increase has been shown to be a hallmark of type I EC. Here, we screened a panel of 23 type I EC tissues and matched typical hyperplasia for mutations in mtDNA and in four oncosupressors/oncogenes, namely PTEN, KRAS, CTNNB1 and TP53. Overall, mtDNA mutations were identified in 69% of cases, while mutational events in nuclear genes occurred in 56% of the cases, indicating that mtDNA mutations may precede the genetic instability of these genes canonically involved in progression from hyperplasia to tumor. Protein expression analysis revealed an increase in mitochondrial biogenesis and activation of oxidative stress response mechanisms in tumor tissues, but not in hyperplasia, in correlation with the occurrence of pathogenic mtDNA mutations. Our results point out an involvement of mtDNA mutations in EC progression and explain the increase in mitochondrial biogenesis of type I EC. Last, since mtDNA mutations occur after hyperplasia, their potential role in contributing to genetic instability may be envisioned.
INTRODUCTION
Mitochondrial DNA (mtDNA) mutations are common somatic events occurring during neoplastic development. They have been frequently associated with virtually all types of cancer (1) and, in specific subsets of tumors, they have been identified as genetic hallmarks of oncocytic transformation (2) (3) (4) (5) (6) (7) (8) . Direct effects of these mutations on the pathogenesis of cancer have only been inferred thus far, whereas metabolic consequences that may be implicated in tumor progression have been suggested and concern the production of reactive oxygen species (ROS), the regulation of apoptosis and the deregulation of oxidative metabolism (9 -11) . The question of whether mtDNA mutations may represent a predisposing or a causative event, or merely a consequence of uncontrolled cell replication with subsequent accumulation of DNA damage, is still a matter of controversy. On the other hand, there is increasing evidence that clearly pathogenic, truncating mtDNA mutations occur as secondary hits to induce the mitochondrial hyperplasia typical of the oncocytic phenotype, a feature acquired by certain tumors during progression (2 -8) . Most such mutations were shown to be homoplasmic, i.e. present in the tumor at 100% mutant load and indicating that all copies of the polyploid mtDNA are mutated. This often implies the ablation of respiratory subunits, leading to a derangement of the oxidative metabolism. Non-oncocytic tumors were instead shown to harbor mainly missense mtDNA mutations, whose pathogenic role and biochemical consequences are more difficult to determine (1, (12) (13) (14) (15) (16) . Furthermore, the hypothesis of a causative role for mtDNA mutations as primary hits in tumor development has seldom been tested in the context of neoplasias for which involvement of known nuclear tumorigenic hits are well ascertained. Hence, timing of the occurrence of mtDNA mutations during tumor progression remains obscure. Uncertain is also whether they accumulate within the context of a deregulated mitochondrial biogenesis (implying an increased mtDNA replication or turnover) or whether they actively contribute to foster mitochondria division by triggering a compensatory effect in response to a respiration damage [for a review see (17) ]. Type I endometrial carcinoma (EC) is a common neoplasia of the female genital tract, 90% of the cases being sporadic. Although EC shows a broad spectrum of morphological patterns, owing to the differentiation ability of the Mül-lerian epithelium, this cancer is usually grouped into two subsets, namely endometrioid EC (type I, estrogen-dependent) and non-endometrioid carcinoma (type II, estrogenindependent). Type I is the most common form, developing usually from hyperplasia and displaying a less aggressive behavior than type II EC. Type I tumors are in fact generally low-grade, low-stage and indolent (18, 19) . Several reasons led us to investigate a role for mtDNA mutations in type I EC. We have previously observed, along with other groups, a significant increase of mitochondrial biogenesis in type I EC, prompting us to hypothesize the involvement of mtDNA mutations (20) . The occurrence of mitochondrial mutations in EC has been seldom reported (21) (22) (23) . Moreover, a Vogelstein-like model for tumor progression (24) has been well characterized for this neoplasia, which is fundamental in the attempt to place mtDNA mutations within cancer development. In fact, a distinct set of gene alterations characterizes a dual mode of carcinogenesis in EC, type I being associated with mutations and/or loss of heterozygosity (LOH) of oncosuppressor PTEN, oncogenes KRAS and CTNNB1 (b-catenin) and, eventually, oncosuppressor TP53 (18, 19, 25) . In particular, PTEN mutations have been suggested to be early events in type I EC development, their occurrence in the precursor lesions being sometimes detected, although the non-clonal origin of hyperplasia may mask or alter genetic findings. We here report a high frequency of mtDNA mutations in a panel of type I ECs, which we correlate with the observed increase in mitochondrial biogenesis and with specific histological findings. Furthermore, we here place mtDNA mutations within the progression model of type I EC upon genotypization, in hyperplastic and matched tumor samples, of the four oncogenes and oncosuppressors involved in type I EC carcinogenesis, inferring functional consequences of mitochondrial genetic lesions.
RESULTS
Type I ECs harbor a plethora of tumor-specific mtDNA mutations
Our first objective was to evaluate whether type I EC presented with the occurrence of tumor-specific mtDNA mutations, like many other tumor types, in order to test the hypothesis that they may underlie the previously demonstrated increase in mitochondrial biogenesis of these neoplasms. To the best of our knowledge, no screening of the whole mtDNA has been performed to date in EC, whereas scattered regions, particularly the regulatory d-loop and the two rRNA genes, have been investigated for microsatellite instability (MSI) (23, 26, 27) . The entire mitochondrial genome sequence was obtained for 23 type I EC samples. For 16 cases, matched hyperplastic tissue was available and hence fully sequenced. This approach enabled us to detect tumor-specific (exclusively present in the tumor mtDNA), non-tumor-specific (present in both the tumor and the hyperplasia mtDNA) and hyperplasia-specific (exclusively present in the hyperplasia mtDNA) variants, and reveal at what stage of transformation such mutations occurred. Overall, 17 tumor-specific variants were found in 11 of 16 matched samples (69%), 10 of which (59%) were predicted to have a pathogenic potential (Table 1) . Six samples for which hyperplastic match was not available displayed six variants that had not been previously described, two of which were predicted to be damaging (Table 1) . Interestingly, a previously described mutation occurred in the proline tRNA gene and had been already associated with cystic fibrosis (28) . In fact, in silico prediction of the tRNA secondary structure indicated an increase in the molecule free energy (dG) from 211.4 in the wild-type to 29.3 in the mutated form, suggesting that the base change might indeed be pathogenic (Supplementary Material, Fig. S1 ). Most tumor-specific mutations were apparently heteroplasmic, an expected finding owing to the heterogeneous composition of the tumor type. It is difficult to infer a global effect of each mutation on different tumor components, especially within mixed neoplasias, which renders evaluation of heteroplasmy of little use. Strikingly, though, eight among the potentially damaging tumor-specific mutations were either homoplasmic or presented a mutation load over 50% as appreciated by the electropherogram data (Table 1) , a threshold likely implying a phenotypic effect, considering this percentage might be well underestimated owing to tumor heterogeneity. Interestingly, two low-heteroplasmy variants were detected in two hyperplastic samples but not in the corresponding tumor tissue (Table 1 ; HE3 and HE23). MSI of d-loop regions was evaluated around positions m.309, m.524 and m.16189, where homopolymeric C-stretches have been reported to display somatic length variation in EC (29) . None of the cases presented length differences between tumor and the corresponding hyperplasia.
Although the sample set was not large enough to define precise correlations between occurrences of mtDNA mutations and grading, a clear-cut tendency for low-grade (G1 -G2) compared with high-grade (G3) tumors to harbor clearly pathogenic mtDNA could be observed (Table 1) . No other correlation between the occurrence of mtDNA mutations and other clinical data resulted statistically significant (Supplementary Material, Table S1 ).
Immunohistochemistry analysis shows oncocytic-like foci in mtDNA-mutated tumors
At variance with what extensively reported in oncocytic tumors, a very small number of mutations described in type I EC were truncating (nonsense and frameshift) mutations. Particularly, two samples harbored a nonsense change in MTCOI complex IV gene and a frameshift change in 
All mtDNA changes found in hyperplastic and tumor samples are listed together with mutations found in canonical nuclear genes (PTEN, KRAS, CTNNB1 and TP53). Single-base deletions in nuclear genes are reported with respect to their cDNA sequence, whereas missense mutations are reported as the change in the corresponding amino acid residue. mtDNA base changes reported in italics are non-tumor-specific variants. AA, amino acid; Het, heteroplasmy; G, tumor grading; PSIC, position-specific independent counts; DB, database; HE, hyperplastic endometrium; TS, tumor-specific variant; Y, yes; N, no; ND, not determined.
MTND6 complex I (CI) gene (Table 1 ; EC5 and EC6, respectively). The impact of an mtDNA mutation may be best understood by means of IHC staining of respiratory complex subunits, which prompted us to verify whether other mutations than disruptive ones may impinge on complexes assembly. In fact, we and others have previously demonstrated that CI disassembly is a hallmark of oncocytic tumors (4, 8, 30) ; hence, a careful evaluation of the occurrence of eosinophilic, oncocytic foci was conducted in all samples. Table 2 summarizes IHC staining for CI nuclear-coded NDUFB6, mitochondria-coded MTND6 and complex V ATP5B [(as a marker of mitochondria abundance (30) ] in the different components of heterogeneous type I ECs. IHC analysis on the same biopsies from which DNA was extracted showed that an oncocytic-like component was present in 13 of 18 (72.2%) samples for which enough material was available, nine of which displayed partial or total loss of staining for the mitochondria-coded respiratory subunit MTND6 (9 of 13, 69.2%), suggesting that oxidative phosphorylation may be partly compromised and confirming association between the loss of CI and oncocytic-like transformation. Six of these nine samples harbored potentially pathogenic mtDNA mutations.
Concordantly with our previous findings (30), the two cases harboring disruptive MTCOI (Fig. 1, EC5 ) and MTND6 (EC6, not shown) mutations did display a predominant histologically confirmed oncocytic component with loss of MTND6 and a marked staining of ATP5B complex V subunit (3, 4, 30) . These data suggest an association between mtDNA pathogenic mutations and acquired oncocytic histological pattern in type I EC.
mtDNA copy number increase may be explained with the occurrence of mtDNA mutations It has been previously shown that increase in mtDNA copy number is a feature of type I EC, independently from the patient age, although this mitochondrial biogenesis parameter was measured upon pooling of cancer samples and comparing with a pooled group of controls (20, 31) . We here attempted a finer analysis by evaluating mtDNA status by comparing every tumor tissue resection with its own hyperplastic match, in order to specifically correlate mtDNA mutation occurrence with a likely compensatory effect leading to copy number increase, similarly to what was demonstrated in oncocytic tumors [for a review see (2)]. Figure 2 displays association between mtDNA copy number and mtDNA mutations. In seven patients (47%), the mtDNA copy number was found to be significantly increased with respect to matched hyperplasia, whereas it was unchanged in seven patients (47%). Only in one single case (EC10), which represents 6% of the analyzed samples, the mtDNA content was significantly reduced compared with hyperplasia. Although these data only partly confirmed what previously reported (4, 20) , it was striking that all but one tumor samples with mtDNA copy number increase harbored one or more damaging mutations [i.e. with positionspecific independent counts (PSIC) scores over 1.7] , whereas 62.5% samples not harboring such mutations showed unchanged or decreased copy number. Association between highly heteroplasmic/homoplasmic damaging mutations and mtDNA copy number increase (Fig. 2, cases EC3 , 5, 6, 8, 9 and 11) was hence significant (P ¼ 0.01, Fisher's exact).
Mitochondrial biogenesis increase is a feature of type I EC, not of hyperplasia mtDNA copy number is a useful parameter in evaluating mitochondrial biogenesis, although not sufficient. Mitochondrial protein content is a complementary marker that may provide indications on the organelles mass within a tissue, not necessarily in a proportional fashion to the DNA content. For 11 samples and their relative hyperplastic matches, enough material was available to perform western blotting, by which both structural proteins [mitochondrial transcription factor (TFAM), VDAC1] and respiratory complex subunits (NDUFA9, SDHA, SDHB, Core II) were analyzed. Protein expression level of TFAM has been described as being closely associated with mtDNA copy number (32), although this was not always the case in our study. In particular, increase in TFAM expression was detected in 9 of 11 tumor samples compared with their matched hyperplastic tissues (82%), regardless of whether mtDNA content was augmented (Fig. 3 ). For instance, TFAM did not appear to be more expressed in EC6 despite this sample displayed the highest mtDNA increase in tumor. Structural protein VDAC1 (porin) is often used as a marker of mitochondrial mass. All samples analyzed showed a higher expression of porin in the tumor, suggesting that increase in mitochondrial mass may be a general feature of type I EC compared with hyperplasia ( Fig. 3) . As a further confirmation of mitochondrial mass increase in tumor tissue, the majority of tumor samples was observed to overexpress subunits belonging to respiratory complexes I (NDUFA9), II (SDHA and SDHB) and III (Core II) when compared with hyperplasia (Fig. 3) .
Effects of mtDNA mutations on the expression of antioxidant enzymes mtDNA mutations have been suggested to contribute to ROS production (1,9,10,33), although we have observed mechanisms of counterbalance of such detrimental effects through the overexpression of antioxidant enzymes by cells harboring such mutations (30) . We attempted to determine whether these mechanisms may also be triggered in EC, in response to the occurrence of mtDNA mutations. Mitochondria-specific enzyme expression levels such as manganese superoxide dismutase (MnSOD) and peroxiredoxin 3 (PRX3) were tested along with the downstream catabolizer of peroxide, catalase (CAT). Although overexpression of MnSOD was observed in 5 of 11 samples (EC1, 3, 5, 6 and 8), the most marked increase was detected in samples harboring the two truncating mutations, namely EC5 and EC6 (Fig. 4) , suggesting that they may have a strong effect on ROS production. Overexpression of CAT and PRX3 correlated well with the occurrence of damaging mutations. EC5 and EC6 tumors displayed the highest levels of both enzymes, whereas a clear-cut increase was also observed in EC9 and EC11 and it could be appreciated also in EC2, EC3 and EC8, all harboring potentially damaging mutations. These data suggest that mtDNA mutations may indeed contribute to ROS production and 
Evaluation of IHC staining is reported for the 18 EC samples for which enough material was available. The expression of mitochondrial abundance marker ATP5B subunit and complex I subunits trigger a compensatory defensive mechanism, leading to overexpression of antioxidant enzymes.
Nuclear genes alterations are common in type I EC
In order to place mtDNA mutations as hits within tumor progression, genes commonly involved in type I EC pathogenesis were screened for point mutations as well as for total or partial LOH. Oncosuppressor PTEN has been reported to be the most frequently altered gene in the initial phases of type I EC, hence it was not surprising that 9 of the 23 tumor samples (39%) harbored point mutations and single-base insertions/deletions (indels) within the coding region of this gene (Table 1 ). In two cases (EC14 and EC23), the mutation was also detected in the matching hyperplastic tissue, suggesting an early inactivation of a single allele, although lack of non-hyperplastic tissue did not allow us to rule out a germ-line origin of the mutation. The percentage of mutated samples was in agreement with what was previously described in EC (18, 34, 35) , whereas the type of mutations detected suggests that MSI may not be involved as a pathogenetic mechanism in our sample set. In fact, no exonic indels ≥ 3 bp were detected, which are typical indicators of MSI in EC (36) . Deletions of whole exons or alleles of PTEN were excluded in all cases by multiplex ligation polypeptide assay (MLPA). (Table 1 ). Two out of 23 patients (9%) harbored activating point mutations in the b-catenin (CTNNB1) oncogene, whereas 2 of 23 (9%) patients harbored inactivating TP53 mutations (Table 1) . In detail, one of such patients harbored two TP53 damaging mutations, one being a nonsense change generating a truncating protein detectable by western blot analysis (data not shown). The heterozygous c.R248W mutation in patient EC19 had been previously described to exert a dominant-negative effect (38) . All KRAS, TP53 and CTNNB1 mutations detected in patients, for which hyperplastic tissue was available, were found to be tumor-specific. Six patients harbored mutations in more than one of the nuclear genes analyzed, four of which also presented mtDNA mutations. On the other hand, six samples harbored tumor-specific mtDNA mutations without any mutation in the oncogenes/oncosuppressors screened (Fig. 5A ). Therefore, no correlation was found between the occurrence of mutations in the analyzed nuclear genes and that of mtDNA mutations, suggesting that the nuclear mutations may not necessarily trigger mtDNA instability, but rather that the mtDNA mutations may prelude, perhaps through ROS increase, to nuclear damage accumulation.
DISCUSSION
In this paper we have undertaken the task to understand the role of mtDNA mutations often called into play as active promoters of tumorigenesis and, in particular, where and how such mutations may enter the progression model of a genetically well-characterized cancer, such as type I EC. We have also investigated mitochondrial biogenesis-related effects of such mutations, whose high frequency in type I EC was here reported for the first time. The strategy of sequencing both canonical oncogenes/oncosuppressors and mtDNA was chosen with the aim of placing mitochondrial mutations within the Vogelstein-like progression model of EC (Fig. 5B) . To the best of our knowledge, this approach has not been implemented thus far, although this may provide indications on whether mtDNA mutations may be directly involved or be a side-effect of tumorigenesis. Moreover, studies in estrogen-dependent EC have indicated mtDNA copy number increase to be a peculiar hallmark of the tumor tissue with respect to normal, proliferative tissue (20, 31) . Interestingly, the high frequency of clearly or potentially pathogenic mtDNA mutations reported here was in significant association with the increase in mtDNA copy number. We have shown that such increase may be regarded as a compensatory effect in response to the occurrence of a pathogenic mtDNA mutation that may determine a respiratory dysfunction and may signal to the nucleus to induce mitochondriogenesis. Such mechanism has been demonstrated, for instance, in colon cancer cell lines (39) as well as in oncocytic tumors [for a review see (2)]. In agreement with this hypothesis, IHC evaluation of separate histological components of the tumor samples revealed that the mitochondrial content was in fact augmented in focal areas of those cases harboring clearly pathogenic mtDNA mutations, in striking resemblance to oncocytic tumors. Moreover, IHC showed a focal respiratory complex disassembly, where an oncocytic-like phenotype could be observed, suggesting that mtDNA mutations may have important functional consequences similar to those demonstrated in oncocytoma (3) (4) (5) 30) . This may explain the increased mitochondrial biogenesis in terms of mtDNA copy number and mitochondrial protein expression. Nonetheless, type I ECs are estrogen-dependent and estrogens are known to induce mitochondrial biogenesis (40, 41) . Hence, a role of these hormones in the induction of mitochondriogenesis in type I EC may not be ruled out and warrants investigation. Endometrial hyperplasia also undergoes estrogen stimulation, which may be difficult to correlate with the finding that mitochondrial biogenesis is found to be augmented in tumor tissues only. A synergistic mechanism may therefore be envisioned in which mtDNA mutation-dependent retrograde signaling of biogenesis induction reinforces a basal estrogen stimulation. The occurrence of often underestimated histological findings such as oncocytic-like foci, in correlation with pathogenic mtDNA mutations was striking. We have previously indicated that most oncocytic tumors harboring disruptive mtDNA mutations retain a low-proliferating, benign behavior because of their inability to undergo adaptation to hypoxia and because of their deranged respiratory metabolism (30) . In fact, the role of respiration in the wavelike tumor progression towards malignancy seems to be fundamental at different stages of adaptation, in response to everchanging microenvironment conditions (42) . It is worth mentioning that type I EC prognosis is generally more favorable than that of type II EC (43) . In this context, it will be important to reveal whether a combined action of estrogens and mtDNA mutations may contribute to maintain the tumor in a less aggressive stage.
Last, we attempted to address the issue of the timing of occurrence of mtDNA mutations in EC development in order to verify whether these genetic lesions may be held responsible for the transition from hyperplasia to neoplasia, regardless of the consequences they have on tumor progression. A predisposing role for mtDNA mutations in cancer has been long debated. Although several groups have demonstrated opposite effects of such mutations on the growth and metastatic potential of cancer cells, according to the tumor and to the mtDNA mutation type (10, 16, 30, (44) (45) (46) , neither a causative nor a secondary role has been proven. In fact, it is not known to date at what stages of the cell transformation mtDNA mutations may begin to appear, although this is fundamental to understand the effects of nonneutral mutations as they strongly impinge on cell metabolism. Our group has previously indicated the occurrence of damaging mtDNA mutations to be a secondary event in tumor progression (5). In the described case, the type of mutation leading to respiratory complex I disassembly led to the induction of the oncocytic phenotype.
In our sample set, likely owing to the heterogeneity of type I EC within the same neoplasia, several mutations were observed to be heteroplasmic, whereas others were clearly homoplasmic. The hetero-versus homoplasmic status of an mtDNA mutation ought to be taken into account when speculating functional consequences. In fact, not only is it known that mtDNA mutations must reach a threshold for phenotypic effect, heteroplasmy degree may also provide indications on the timing of occurrence within the (clonal) expansion of the tumor. Any mtDNA mutation in fact must arise in a single mtDNA copy and then shift towards the mutated or the wildtype allele, a process that may be random or driven by purifying selection. Whatever the mechanism, we showed here that mtDNA mutations could be detected in most samples, regardless of the presence of mutations in the canonically involved nuclear genes. These results might be suggestive of a primary role of such mutations in the transition from simple hyperplasia to neoplasia, as hyperplastic tissues were not found (with very few exceptions) to harbor mutations. All mtDNA variants detected in hyperplasia were in fact clear haplogroup determinants (see Materials and Methods for mtDNA sequences quality check). However, caution is warranted since other oncogenes/oncosuppressors may be responsible to drive tumorigenesis, apart from those we screened here, in cases where no nuclear mutations were detected. Moreover, several tumor-specific mtDNA mutations were not potentially pathogenic and, furthermore, they were heteroplasmic. They may hence be regarded as side-effects of tumorigenesis, which may probably not impinge on tumor progression. Nevertheless, the high percentage of mtDNA mutations reported here in type I EC suggests the potential use of these mutations as biomarkers for the distinction of tumor versus hyperplastic tissues, as it is known that in low cellularity samples, changes in mtDNA are more easily detected than the ones in nuclear genes (47, 48) .
Interestingly, similar to previously characterized mtDNAmutated cell models (30), a tumor-specific compensatory mechanism was also observed in terms of overexpression of anti-oxidant enzymes in samples harboring pathogenic mtDNA mutations. Although one of the consequences of the occurrence of mtDNA mutations may be the increase in ROS production, cells attempt to counteract the detrimental effects of ROS excess, which also implies that genomic instability may not be an inevitable consequence of a respiratory derangement. Further studies on cell models are warranted to confirm that nuclear gene mutations are not a consequence of mitochondrial mutation-dependent ROS increase, although our ex vivo study provides the basis for such hypothesis. On the other hand, if mtDNA mutations were to contribute to nuclear ones, they should probably occur first in hyperplastic cells, which is not the case here.
Taken together, our experiments show that mtDNA mutations may be placed within the context of tumor progression along with mutations in canonical oncogenes/oncosuppressors as they determine specific phenotypes and have functional consequences on cancer cells. mtDNA mutations do not contribute to hyperplastic development and may not be considered as causative hits leading to neoplasia, however, they may be responsible and provide an explanation for specific molecular and histological findings whose role in pathology may be useful as tumor diagnostic markers and predictors of prognosis.
MATERIALS AND METHODS

Sample collection and diagnosis
Twenty-three type I endometrioid EC and 16 matching simple hyperplasia (49) frozen samples were obtained from patients submitted to laparotomic hysterectomy at the Department of Gynecology, Obstetrics and Neonatology, University of Bari, Italy, between January 2008 and June 2009. None of the patients had received any treatment (radiotherapy, chemotherapy or hormone therapy) before surgery. Stage, myometrial invasion and grading of EC were assigned according to the International Federation of Gynecology and Obstetrics. All specimens were collected immediately after hysterectomy, and divided in two halves. One half was used for immunohistochemistry (IHC) and the other was snap-frozen in liquid nitrogen, stored at280 8C and used for protein and nucleic acid extraction. In every case, diagnosis of endometrial cancer or hyperplasia was confirmed by pathologic evaluation in the specimens used for IHC.
All clinical specimens were collected under protocols approved by the Institutional Review Board.
In order to assess the somatic nature of two hyperplasia mtDNA mutations, the non-tumor and non-hyperplastic tissue was dissected for two samples from the same patient's normal peritumoral endometrium. Samples clinical data are available in Supplementary Material, Table S1 .
Mitochondrial DNA sequencing and analysis
The entire mtDNA sequence of all tumor and hyperplastic samples was obtained with the MitoAll re-sequencing kit and analyzed with the SeqScape software (Applied Biosystems, Foster City, CA, USA) as previously described (5) . Prediction of pathogenic potential of missense mutations was performed with PolyPhen (www. tux.embl-heidelberg.de/ ramensky/polyphen.cgi) as previously described (5) . Briefly, PolyPhen is based on sequence comparison with homologous proteins. Profile scores (PSIC) are generated for the allelic variants and represent the logarithmic ratio of the likelihood of a given amino acid occurring at a particular site relative to the likelihood of this amino acid occurring at any site (background frequency). Generally, PSIC score differences . 2 indicate a damaging effect, scores between 1.5 and 2 suggest that the variant is possibly damaging and scores , 1.5 indicate that the variant is benign. For mtDNA variability analysis and haplogroup assignment, classifying tools within the public resource HmtDB (50) were utilized, as described in detail previously (30) . The entire set of the complete mitochondrial genome sequences from tumor samples was deposited in HmtDB (www.hmtdb.uniba.it). The complete list of the HmtDB identifiers is reported in Supplementary Material, Table S2 .
Human mitochondrial genomes quality check
The entire set of tumor and hyperplasia mitochondrial genomes was analyzed by applying the classifier tool available through HmtDB, which provided an alignment of both mtDNA sequences (from each tumor and its matched hyperplasia, where available) with the revised version of the Cambridge Reference Sequence (51) . Variant sites were compared with the most up-to-date human mtDNA haplogroup classification as annotated in Phylotree (52). Haplogroup defining sites and variability values were used to define each genome haplogroup. When the haplogroup could not be immediately assigned with a probability equal to 100%, revision of the electropherogram was performed to reveal incorrect software interpretation of the mtDNA assembly. Overall, variability was estimated on a set of about 6000 human mitochondrial genomes. Low variability values were hence taken as an indication that the variant was not a polymorphism, hence not present in the population with a frequency .1%.
DNA extraction and mtDNA copy number evaluation
Total DNA was prepared from 20 mg of endometrial tissue using NucleoSpin Tissue Kit (Macherey-Nagel, Düren, Germany) and stored at 2208C. The mtDNA content was measured as previously described (20) . Briefly, real-time polymerase chain reaction (PCR) was performed using an ABI Prism 7000 real-time PCR (Applied Biosystems). The mtDNA quantity was related to the nuclear DNA (nDNA) amount by the simultaneous measurement of the nDNA. The method was validated by evaluating the equal reaction efficiency of the two amplicons. Each sample was analyzed in triplicate in three to four different experiments. The PCR was performed separately for the target MTND1 gene and the reference b-actin (ACTB) gene. MLPA using the PTEN probe kit (P225-B2-see below) showed that all samples analyzed were diploid for the normalizer gene, confirming the previously demonstrated lack of aneuplody in type I EC (18, 53) . The difference in threshold cycle values (DCt, namely CtND1 -CtACTB) was used as a measure of the relative abundance of the mitochondrial genome. Hyperplasia mtDNA copy number was then taken as a reference (calibrator) and the number of fold increase of the mtDNA content in tumor was calculated as 2 2DCt (tumor) /2 2DCt (hyperplasia) . 
Western blotting
IHC analysis
IHC analysis with antibodies against MTND6 subunit of complex I and ATP5B subunit of complex V (Invitrogen), along with haematoxylin/eosin staining was performed on paraffin-embedded tissue sections as previously described (3 -5,30) .
Tumors genotypization
PTEN mutation analysis of all nine coding exons was performed by PCR. The reaction mixture was denatured at 968C for 10 min and subjected to 35 polymerization cycles (968C for 30 s, 588C for 30 s, 728C for 1 min; final extension 728C for 7 min). TP53 mutation analysis of coding exons 2 -11 was performed by PCR. The reaction mixture was denatured at 958C for 10 min and subjected to 40 polymerization cycles (958C for 30 s, touch-down 60 -558C for 30 s, 728C for 45 s; final extension 728C for 7 min). KRAS mutation analysis of coding exons 1 -4 was performed by PCR. The reaction mixture was denatured at 958C for 5 min and subjected to 40 polymerization cycles (958C for 30 s, 548C for 30 s, 728C for 30 s; final extension 728C for 7 min). Mutations analysis of exon 3 of the CTNNB1 gene, encoding critical phosphorylation sites, was performed by PCR. The reaction mixture was denatured at 958C for 10 min and subjected to 40 polymerization cycles (958C for 30 s, 568C for 30 s, 728C for 1 min; final extension 728C for 7 min). All PCR reactions were carried out using FastStart Taq DNA Polymerase (Roche) and run in a 2720 thermocycler (Applied Biosystems), hence purified using Multiscreen Filter Plates for DNA clean-up (Millipore, Billerica, MA, USA). Sanger sequencing was performed with Big Dye v3.1 (Applied Biosystems) according to the manufacturer's instructions and run in the ABI 3730 Genetic Analyzer automated sequencing machine (Applied Biosystems). All mutations were confirmed by sequencing on both strands on a second PCR product.
Multiplex ligation polypeptide assay
MLPA was performed using the PTEN probe kit (P225-B2) (MRC-Holland BV, Amsterdam, The Netherlands) according to manufacturer's instructions. Briefly, 50 ng of genomic DNA in 5 ml of TE was heat-denatured (5 min at 988C) and incubated with the probe set for 16 h at 608C. The hybridized products were ligated (15 min at 548C), PCR-amplified (35 cycles: 30 s at 958C; 30 s at 608C; 60 s at 728C; final elongation: 20 min at 728C) and separated by electrophoresis on an automated sequencer. DNA from healthy individuals was used as normal control. Data were evaluated using Coffalyser v.8. All samples were assayed in two independent MLPA reactions.
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